Rep. Chris Collins (R-N.Y.) was indicted Wednesday on federal insider trading charges. Prosecutors alleged that he used information he received while on the board of an Australian biotechnology firm, Innate Immunotherapeutics, to tip off his son and others to sell the company’s stock before a damaging report on the company’s lack of success with a drug to treat multiple sclerosis.
The Associated Press has a story about the indictment and the complaint filed by the Securities and Exchange Commission.
Here’s a look at Kaiser Health News’ earlier coverage of Collins’ relationship with the company:
Congressman’s Ties To Foreign Biotech Draw Criticism
Report: Congressional Ethics Office Probing Rep. Chris Collins’ Aussie Investment
Rep. Chris Collins’ Australian Stock Bet Looks Bleaker
Trump’s HHS Nominee Got A Sweetheart Deal From A Foreign Biotech Firm
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.Some elements may be removed from this article due to republishing restrictions. If you have questions about available photos or other content, please contact khnweb@kff.org.
